Home
½ÃÀÛÆäÀÌÁö
Áö³È£º¸±â
·Î±×ÀÎ
ȸ¿ø°¡ÀÔ
±¸µ¶½Åû
Àüü±â»ç
2024-03-28 ¸ñ 18:48
±â»ç°Ë»ö
Cover Story
¼øȯ±â
³»ºÐºñ
È£Èí±â
¼Òȱâ
½Å°æ°ú
Á¤½Å°Ç°
°¨¿°³»°ú
Sub Story
Interview
Drug Review
Conference Report
Late Breaking Studies
Expert Opinion
Primary Expert Opinion
The Rare Disease
ÇмúÀÚ¹®À§¿ø
RTM
»ó´Ü¿©¹é
񃯇
(Àüü 23°Ç)
Á¦¸ñº¸±â
Á¦¸ñº¸±â
Á¦¸ñ+³»¿ë
[Late Breaking Studies]
CCB/ARB ±â¹Ý º¹ÇÕÁ¦ ¸®¾ó¿ùµå È¿°ú È®ÀÎ
ÀÓ¼¼Çü ±âÀÚ
2019-10-08 15:58
[Sub Story]
Çѱ¹ÀÎ ´ç´¢º´ ÀâÀ¸·Á¸é¡¦
ÀÌ»óµ· ±âÀÚ
2019-10-08 15:57
[Sub Story]
PCI¡¤½É¹æ¼¼µ¿ ȯÀÚ NOAC ±â¹Ý Ç×Ç÷Àü¿ä¹ý ±¸¼º
ÀÓ¼¼Çü ±âÀÚ
2019-10-08 15:56
[Sub Story]
ºñ½ºÅ¸Æ¾°è º´¿ë·Ð ³ª¿À±â±îÁö
ÀÌ»óµ· ±âÀÚ
2019-10-08 15:55
[Interview]
¼Õ½¬¿î º¹ÇÕÁ¦ ó¹æ ´Ã¸é Á¶Àý·ü Àçµµ¾à ±âȸ ¿Ã °Í
ÀÌ»óµ· ±âÀÚ
2019-10-08 15:54
¶óÀÎ
[Sub Story]
RAS¾ïÁ¦Á¦ + ÀÌ´¢Á¦, º´¿ëÀ¸·Î Ç÷°üÇÕº´Áõ Àå±â°£ ¸·¾Æ
ÀÌ»óµ· ±âÀÚ
2019-10-08 15:54
[Cover Story]
¡®´ÙÁ¦¾à¹°¿ä¹ý¡¯ ½Ã´ë ¼ÒÀÓ ´ÙÇؾß!
ÀÌ»óµ· ±âÀÚ
2019-10-08 15:53
[Sub Story]
º´¿ë½Ã±â °¥¼ö·Ï »¡¶óÁ®
ÀÌ»óµ· ±âÀÚ
2019-10-08 15:46
[Sub Story]
RAS¾ïÁ¦Á¦ + CCB, ½ÉÇ÷°ü»ç°Ç À§Çè À¯ÀÇÇÏ°Ô °¨¼Ò
ÀÌ»óµ· ±âÀÚ
2019-10-08 15:42
[Sub Story]
ARB/CCB/ÀÌ´¢Á¦ 3Á¦º´¿ë ÁÖµµ
ÀÌ»óµ· ±âÀÚ
2019-10-08 15:35
¶óÀÎ
[Sub Story]
Çѱ¹ÀÎ ÁöÁúÄ¡·á ¼À¹ý º¹ÀâÇØÁ³´Ù
ÀÌ»óµ· ±âÀÚ
2019-10-08 15:05
[Sub Story]
ºÒ¼¼Ãâ ½ºÅ¸Æ¾ÀÌ¶óµµ ¼±¹ßÅõ¼ö È¥ÀÚ´Â Èûµé¾î
ÀÌ»óµ· ±âÀÚ
2019-10-08 14:44
[Sub Story]
¡°CVD ¿¹¹æÀü·«, È¿°ú¡¤¾ÈÀü¼º ¸ðµÎ °í·ÁÇؾߡ±
ÀÓ¼¼Çü ±âÀÚ
2019-10-08 14:23
[Sub Story]
»õ·Î¿î DAPT Àü·« ±Ù°ÅÃàÀû Áß
ÀÓ¼¼Çü ±âÀÚ
2019-10-08 14:10
[Sub Story]
¸®¹Ù·Ï»ç¹Ý ±â¹Ý Ç×Ç÷Àü¿ä¹ý ÃâÇ÷À§Çè À¯ÀÇÇÏ°Ô °¨¼Ò
ÀÓ¼¼Çü ±âÀÚ
2019-10-08 13:55
¶óÀÎ
[Sub Story]
ºñ¿µî¼º ÀÔÁõÇÑ ´Ùºñ°¡Æ®¶õ ÀÌÁßÇ×Ç÷Àü¿ä¹ý
ÀÓ¼¼Çü ±âÀÚ
2019-10-08 13:53
[Sub Story]
¾ÆÇÈ»ç¹Ý ¾Æ½ºÇǸ° ´ëü DAPT ÀÚ°Ý È®ÀÎ
ÀÓ¼¼Çü ±âÀÚ
2019-10-08 13:51
[Sub Story]
Ç÷´ç°ÇÏÁ¦ ó¹æÀÌ º´¿ëÀ¸·Î °£ ±î´ßÀº?
ÀÌ»óµ· ±âÀÚ
2019-10-08 12:28
[Interview]
¼øÀÀµµ ³ôÀÌÀÚ°í ¸¸µç Ç÷¾Ð¡¤ÁöÁúÄ¡·á ¡®SPC¡¯
ÀÌ»óµ· ±âÀÚ
2019-10-08 12:20
[Deep in Guideline]
¸¸¼º±âħ ¼Ò¾Æ ȯÀÚ GERD Ä¡·á, ÆǺ° ÈÄ ½ÃÇà °Á¶
ÀÓ¼¼Çü ±âÀÚ
2019-10-08 12:15
-
1
2
-
¿©¹é
Sub
news
¡°ACEI ÀÓ»ó±Ù°Å ³õ°í, ȯÀÚ ¼³µæÇÏÀÚ¡±
Q. Ç÷¾Ð°ÇÏ Ãø¸é¿¡¼ ACEIÀÇ Æ¯¼ºÀº?ù...
¡°SGLT-2i Ȳ±Ý±â´Â TZD¿Í º´¿ëÀ¸·ÎºÎÅÍ¡±
Q. SGLT-2iÀÇ °è¿È¿°ú¿¡ ´ëÇÑ °ßÇØ´Â...
¡°°í°µµ ½ºÅ¸Æ¾ Á¦Á¦ È¿°ú ´ëµîÇϳª ¾ÈÀü¼º ´Ù¸¦ ¼öµµ¡±
Q. CAD ȯÀÚÀÇ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·áÀü·«Àº?...
¿©¹é
¿©¹é
Back to Top